Adaptive BiotechnologiesADPT
ADPT
About: Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
Employees: 709
0
Funds holding %
of 6,815 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
65% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 20
56% more call options, than puts
Call options by funds: $403K | Put options by funds: $259K
48% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 44
36% more capital invested
Capital invested by funds: $543M [Q2] → $737M (+$194M) [Q3]
6% more funds holding
Funds holding: 176 [Q2] → 187 (+11) [Q3]
4.2% less ownership
Funds ownership: 101.84% [Q2] → 97.64% (-4.2%) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7
15%
upside
Avg. target
$8
32%
upside
High target
$9
48%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
BTIG Mark Massaro 69% 1-year accuracy 20 / 29 met price target | 48%upside $9 | Buy Maintained | 18 Dec 2024 |
Piper Sandler David Westenberg 67% 1-year accuracy 26 / 39 met price target | 15%upside $7 | Overweight Maintained | 11 Nov 2024 |
Financial journalist opinion
Based on 3 articles about ADPT published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
Pairing Adaptive Biotechnologies' clonoSEQ MRD results with NeoGenomics' COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum Pairing Adaptive Biotechnologies' clonoSEQ MRD results with NeoGenomics' COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum
Neutral
GlobeNewsWire
1 week ago
Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025
SEATTLE, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today that the new Medicare Clinical Laboratory Fee Schedule (CLFS) rate for its next-generation sequencing (NGS)-based clonoSEQ® test for minimal – or measurable – residual disease (MRD) assessment is now in effect as of January 1, 2025. The CLFS rate for clonoSEQ (PLA 0364U) was set at $2,007, consistent with the final gapfill rate recommendation for the test.
Neutral
GlobeNewsWire
1 week ago
Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SEATTLE, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Negative
Benzinga
1 month ago
Top 3 Health Care Stocks That May Collapse This Quarter
As of Dec. 11, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Neutral
GlobeNewsWire
1 month ago
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL
Neutral
GlobeNewsWire
1 month ago
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting
SEATTLE, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in more than 65 abstracts across eight different types of blood cancer at the 66th Annual Meeting of the American Society of Hematology (ASH) taking place December 7-10, 2024, in San Diego. Among these abstracts are a plenary session presentation, a late-breaking abstract and 25 other oral presentations.
Positive
Zacks Investment Research
1 month ago
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?
Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Positive
Seeking Alpha
1 month ago
Adaptive Biotechnologies: Making Some Progress
Adaptive Biotechnologies posted strong Q3 results, beating expectations and reducing losses, while management has done a good job of reducing quarterly cash burn rates. The company's MRD segment, driven by clonoSEQ, continues to show significant growth, and the company's balance sheet remains strong. An updated analysis around Adaptive Biotechnologies follows in the paragraphs below.
Positive
Zacks Investment Research
2 months ago
Wall Street Analysts Predict a 31.36% Upside in Adaptive Biotechnologies (ADPT): Here's What You Should Know
The consensus price target hints at a 31.4% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
Seeking Alpha
2 months ago
Adaptive Biotechnologies Corporation (ADPT) Q3 2024 Earnings Call Transcript
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Karina Calzadilla - Head of IR Chad Robins - CEO and Co-Founder Kyle Piskel - CFO Susan Bobulsky - Chief Commercial Officer Conference Call Participants Dan Brennan - TD Cowen Mark Massaro - BTIG Matt Sykes - Goldman Sachs Maggie Boeye - William Blair Corey Rosenbaum - Scotiabank Operator Good day, and welcome to Adaptive Biotechnologies Third Quarter Financial Results [Operator Instructions]. As a reminder, this call may be recorded.
Charts implemented using Lightweight Charts™